MX2020002033A - Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas. - Google Patents
Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas.Info
- Publication number
- MX2020002033A MX2020002033A MX2020002033A MX2020002033A MX2020002033A MX 2020002033 A MX2020002033 A MX 2020002033A MX 2020002033 A MX2020002033 A MX 2020002033A MX 2020002033 A MX2020002033 A MX 2020002033A MX 2020002033 A MX2020002033 A MX 2020002033A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- bcl
- inhibitors
- treatment
- condensed heterocyclic
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000001613 neoplastic effect Effects 0.000 title abstract 2
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
- G01N21/763—Bioluminescence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plasma & Fusion (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La descripción incluye compuestos de fórmula (A): [ver Fórmula (A)] en donde R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, y R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, y Q4, se definen aquí; también se describe un método durante el tratamiento de una enfermedad neoplásica, una enfermedad autoinmune, una enfermedad neurodegenerativa con estos compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549081P | 2017-08-23 | 2017-08-23 | |
| US201862615007P | 2018-01-09 | 2018-01-09 | |
| PCT/US2018/047411 WO2019040550A1 (en) | 2017-08-23 | 2018-08-22 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002033A true MX2020002033A (es) | 2020-08-20 |
Family
ID=63490700
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002033A MX2020002033A (es) | 2017-08-23 | 2018-08-22 | Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas. |
| MX2020002032A MX2020002032A (es) | 2017-08-23 | 2018-08-22 | Inhibidores de bcl-2. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002032A MX2020002032A (es) | 2017-08-23 | 2018-08-22 | Inhibidores de bcl-2. |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US11365206B2 (es) |
| EP (3) | EP3672975B1 (es) |
| JP (2) | JP7467331B2 (es) |
| KR (2) | KR102680163B1 (es) |
| CN (4) | CN116425771A (es) |
| AU (2) | AU2018321496B2 (es) |
| CA (2) | CA3073446A1 (es) |
| DK (2) | DK3672976T3 (es) |
| ES (2) | ES2948287T3 (es) |
| FI (2) | FI3672975T3 (es) |
| IL (1) | IL272762B2 (es) |
| MX (2) | MX2020002033A (es) |
| SG (1) | SG11202001553UA (es) |
| WO (2) | WO2019040573A1 (es) |
| ZA (1) | ZA202001301B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002033A (es) | 2017-08-23 | 2020-08-20 | Guangzhou Lupeng Pharmaceutical Company Ltd | Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas. |
| MX2020011495A (es) | 2018-04-29 | 2021-01-15 | Beigene Ltd | Inhibidores de bcl-2. |
| WO2020041405A1 (en) | 2018-08-22 | 2020-02-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US20220372042A1 (en) * | 2019-10-03 | 2022-11-24 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021083135A1 (en) * | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| US12552784B2 (en) | 2019-12-27 | 2026-02-17 | Newave Pharmaceutical Inc. | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| CN115484933A (zh) * | 2020-02-24 | 2022-12-16 | 广州麓鹏制药有限公司 | 含有bcl2抑制剂的热熔挤出固体分散体 |
| KR20230002419A (ko) | 2020-04-15 | 2023-01-05 | 베이진 엘티디 | Bcl-2 억제제 |
| US20240166646A1 (en) | 2020-12-22 | 2024-05-23 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| CN113694059B (zh) * | 2021-03-24 | 2023-09-26 | 浙江大学 | Nl101在制备治疗急性、慢性排斥反应药物中的应用 |
| WO2023122000A1 (en) * | 2021-12-20 | 2023-06-29 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US20250099481A1 (en) * | 2022-01-12 | 2025-03-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US11964990B2 (en) | 2022-01-21 | 2024-04-23 | Abbvie Inc. | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
| CN116236583A (zh) * | 2023-03-30 | 2023-06-09 | 广州麓鹏制药有限公司 | 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用 |
| CN116270660A (zh) * | 2023-03-30 | 2023-06-23 | 广州麓鹏制药有限公司 | 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| WO2005024636A1 (ja) | 2003-09-04 | 2005-03-17 | Hitachi Ulsi Systems Co., Ltd. | 半導体装置 |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| GB0623209D0 (en) * | 2006-11-21 | 2007-01-03 | F2G Ltd | Antifungal agents |
| WO2009036035A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| NZ601350A (en) | 2007-11-16 | 2013-08-30 | Abbvie Inc | Method of treating arthritis |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| NZ592801A (en) | 2008-12-05 | 2013-08-30 | Abbvie Inc | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN102448959B (zh) | 2009-05-26 | 2015-06-17 | 艾伯维巴哈马有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| JP5743482B2 (ja) | 2010-10-15 | 2015-07-01 | 株式会社アルファ | エスカッション部材のハンドルベースへの連結方法 |
| CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CN107266435A (zh) | 2010-11-23 | 2017-10-20 | Abbvie 公司 | 细胞凋亡诱导剂的盐和晶形 |
| EP2935284A4 (en) * | 2012-12-21 | 2016-04-27 | Abbvie Inc | HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS |
| EP3293185A1 (en) | 2013-03-13 | 2018-03-14 | AbbVie Inc. | Processes for the preparation of an apoptosis-inducing agent |
| CN104513252B (zh) * | 2013-09-26 | 2017-11-10 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| EP3565815B1 (en) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| HUE060310T2 (hu) | 2017-04-18 | 2023-02-28 | Shanghai Fochon Pharmaceutical Co Ltd | Apoptosis-indukáló szerek |
| MX2020002033A (es) | 2017-08-23 | 2020-08-20 | Guangzhou Lupeng Pharmaceutical Company Ltd | Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas. |
| WO2020041405A1 (en) | 2018-08-22 | 2020-02-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US20220372042A1 (en) | 2019-10-03 | 2022-11-24 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| US12552784B2 (en) | 2019-12-27 | 2026-02-17 | Newave Pharmaceutical Inc. | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
-
2018
- 2018-08-22 MX MX2020002033A patent/MX2020002033A/es unknown
- 2018-08-22 WO PCT/US2018/047444 patent/WO2019040573A1/en not_active Ceased
- 2018-08-22 CA CA3073446A patent/CA3073446A1/en active Pending
- 2018-08-22 EP EP18765254.0A patent/EP3672975B1/en active Active
- 2018-08-22 IL IL272762A patent/IL272762B2/en unknown
- 2018-08-22 DK DK18765259.9T patent/DK3672976T3/da active
- 2018-08-22 FI FIEP18765254.0T patent/FI3672975T3/fi active
- 2018-08-22 CN CN202310267471.8A patent/CN116425771A/zh active Pending
- 2018-08-22 MX MX2020002032A patent/MX2020002032A/es unknown
- 2018-08-22 JP JP2020510576A patent/JP7467331B2/ja active Active
- 2018-08-22 SG SG11202001553UA patent/SG11202001553UA/en unknown
- 2018-08-22 ES ES18765254T patent/ES2948287T3/es active Active
- 2018-08-22 AU AU2018321496A patent/AU2018321496B2/en active Active
- 2018-08-22 WO PCT/US2018/047411 patent/WO2019040550A1/en not_active Ceased
- 2018-08-22 KR KR1020207008179A patent/KR102680163B1/ko active Active
- 2018-08-22 FI FIEP18765259.9T patent/FI3672976T3/fi active
- 2018-08-22 ES ES18765259T patent/ES2971457T3/es active Active
- 2018-08-22 CA CA3073445A patent/CA3073445A1/en active Pending
- 2018-08-22 KR KR1020207008178A patent/KR102705861B1/ko active Active
- 2018-08-22 EP EP18765259.9A patent/EP3672976B1/en active Active
- 2018-08-22 DK DK18765254.0T patent/DK3672975T3/da active
- 2018-08-22 JP JP2020510610A patent/JP7467332B2/ja active Active
- 2018-08-22 CN CN201880067185.4A patent/CN111448198B/zh active Active
- 2018-08-22 EP EP23167453.2A patent/EP4227311A1/en active Pending
- 2018-08-22 CN CN201880067225.5A patent/CN111511748B/zh active Active
- 2018-08-22 AU AU2018322059A patent/AU2018322059C1/en active Active
- 2018-08-22 CN CN202310439771.XA patent/CN116621860A/zh active Pending
-
2020
- 2020-02-20 US US16/795,720 patent/US11365206B2/en active Active
- 2020-02-20 US US16/795,884 patent/US11279711B2/en active Active
- 2020-02-28 ZA ZA2020/01301A patent/ZA202001301B/en unknown
-
2022
- 2022-03-18 US US17/698,289 patent/US11680072B2/en active Active
- 2022-06-15 US US17/840,957 patent/US11993610B2/en active Active
-
2023
- 2023-05-03 US US18/142,842 patent/US12410190B2/en active Active
-
2024
- 2024-04-22 US US18/641,869 patent/US20240425520A1/en not_active Abandoned
- 2024-12-06 US US18/971,214 patent/US20250179090A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002033A (es) | Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas. | |
| PH12021500014A1 (en) | Fused ring compounds | |
| WO2017132474A8 (en) | Bcl-2 inhibitors | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| EP4635568A3 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| MX389672B (es) | Inhibidores de ssao de aminopirimidina | |
| JOP20190182B1 (ar) | أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| WO2021066873A8 (en) | Condensed heterocycles as bcl-2 inhibitors | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| MX381994B (es) | Inhibidor de janus quinasa. | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| SA519402288B1 (ar) | مركب بيريميدين واستخداماته الصيدلانية | |
| WO2018153508A3 (en) | INHIBITORS OF SULFOXIMINE GLYCOSIDASE | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| IL283823A (en) | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease | |
| EP4286001A3 (en) | Benzoylglycine derivatives and methods of making and using same | |
| SG11201810725WA (en) | Novel β-lactamase inhibitors |